M H Napimoga1, E P Rocha1, C A Trindade-da-Silva2, A P D Demasi1, E F Martinez1, C G Macedo1, H B Abdalla3, A Bettaieb4, F G Haj5, J T Clemente-Napimoga1, B Inceoglu2, B D Hammock2. 1. São Leopoldo Mandic Institute and Research Center, Campinas, Brazil. 2. Department of Entomology and Nematology and UC Davis Comprehensive Cancer Center, University of California, Davis, CA, USA. 3. Laboratory of Orofacial Pain, Department of Physiology, Piracicaba Dental School, State University of Campinas, Piracicaba, SP, Brazil. 4. Department of Nutrition, University of Tennessee-Knoxville, Knoxville, TN, USA. 5. Nutrition Department, University of California, Davis, CA, USA.
Abstract
BACKGROUND AND OBJECTIVE: Soluble epoxide hydrolase (sEH) is an enzyme in the arachidonate cascade which converts epoxy fatty acids (EpFAs), such as epoxyeicosatrienoic acids (EETs) produced by cytochrome P450 enzymes, to dihydroxy-eicosatrienoic acids. In the last 20 years with the development of inhibitors to sEH it has been possible to increase the levels of EETs and other EpFAs in in vivo models. Recently, studies have shown that EETs play a key role in blocking inflammation in a bone resorption process, but the mechanism is not clear. In the current study we used the sEH inhibitor (1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea [TPPU]) to investigate the immunomodulatory effects in a mouse periodontitis model. MATERIAL AND METHODS: Mice were infected on days 0, 2, and 4 with Aggregatibacter actinomycetemcomitans and divided into groups (n = 6) that were treated orally, daily for 15 days, with 1 mg/kg of TPPU. Then, the mice were killed and their jaws were analyzed for bone resorption using morphometry. Immunoinflammatory markers in the gingival tissue were analyzed by microarray PCR or western blotting. RESULTS: Infected mice treated with TPPU showed lower bone resorption than infected mice without treatment. Interestingly, infected mice showed increased expression of sEH; however, mice treated with TPPU had a reduction in expression of sEH. Besides, several proinflammatory cytokines and molecular markers were downregulated in the gingival tissue in the group treated with 1 mg/kg of TPPU. CONCLUSION: The sEH inhibitor, TPPU, showed immunomodulatory effects, decreasing bone resorption and inflammatory responses in a bone resorption mouse model.
BACKGROUND AND OBJECTIVE:Soluble epoxide hydrolase (sEH) is an enzyme in the arachidonate cascade which converts epoxy fatty acids (EpFAs), such as epoxyeicosatrienoic acids (EETs) produced by cytochrome P450 enzymes, to dihydroxy-eicosatrienoic acids. In the last 20 years with the development of inhibitors to sEH it has been possible to increase the levels of EETs and other EpFAs in in vivo models. Recently, studies have shown that EETs play a key role in blocking inflammation in a bone resorption process, but the mechanism is not clear. In the current study we used the sEH inhibitor (1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea [TPPU]) to investigate the immunomodulatory effects in a mouseperiodontitis model. MATERIAL AND METHODS:Mice were infected on days 0, 2, and 4 with Aggregatibacter actinomycetemcomitans and divided into groups (n = 6) that were treated orally, daily for 15 days, with 1 mg/kg of TPPU. Then, the mice were killed and their jaws were analyzed for bone resorption using morphometry. Immunoinflammatory markers in the gingival tissue were analyzed by microarray PCR or western blotting. RESULTS: Infected mice treated with TPPU showed lower bone resorption than infected mice without treatment. Interestingly, infected mice showed increased expression of sEH; however, mice treated with TPPU had a reduction in expression of sEH. Besides, several proinflammatory cytokines and molecular markers were downregulated in the gingival tissue in the group treated with 1 mg/kg of TPPU. CONCLUSION: The sEH inhibitor, TPPU, showed immunomodulatory effects, decreasing bone resorption and inflammatory responses in a bone resorption mouse model.
Authors: Todd R Harris; Ahmed Bettaieb; Sean Kodani; Hua Dong; Richard Myers; Nipavan Chiamvimonvat; Fawaz G Haj; Bruce D Hammock Journal: Toxicol Appl Pharmacol Date: 2015-03-28 Impact factor: 4.219
Authors: Marcelo H Napimoga; Carlos A T da Silva; Vanessa Carregaro; Thais S Farnesi-de-Assunção; Poliana M Duarte; Nathalie F S de Melo; Leonardo F Fraceto Journal: J Immunol Date: 2012-06-15 Impact factor: 5.422
Authors: Sumanta Kumar Goswami; Debin Wan; Jun Yang; Carlos A Trindade da Silva; Christophe Morisseau; Sean D Kodani; Guang-Yu Yang; Bora Inceoglu; Bruce D Hammock Journal: J Pharmacol Exp Ther Date: 2016-03-17 Impact factor: 4.030
Authors: R de Waal Malefyt; C G Figdor; R Huijbens; S Mohan-Peterson; B Bennett; J Culpepper; W Dang; G Zurawski; J E de Vries Journal: J Immunol Date: 1993-12-01 Impact factor: 5.422
Authors: Marcelo H Napimoga; Juliana T Clemente-Napimoga; Cristina G Macedo; Fabiana F Freitas; Rafael N Stipp; Felipe A Pinho-Ribeiro; Rubia Casagrande; Waldiceu A Verri Journal: J Nat Prod Date: 2013-11-18 Impact factor: 4.050
Authors: Carlos A Trindade-da-Silva; Juliana T Clemente-Napimoga; Henrique B Abdalla; Sergio Marcolino Rosa; Carlos Ueira-Vieira; Christophe Morisseau; Waldiceu A Verri; Victor Angelo Martins Montalli; Bruce D Hammock; Marcelo H Napimoga Journal: FASEB J Date: 2020-05-13 Impact factor: 5.191
Authors: Debin Wan; Jun Yang; Cindy B McReynolds; Bogdan Barnych; Karen M Wagner; Christophe Morisseau; Sung Hee Hwang; Jia Sun; René Blöcher; Bruce D Hammock Journal: Front Pharmacol Date: 2019-05-08 Impact factor: 5.810